Multitarget Drug Discovery for Tuberculosis and Other Infectious Diseases

Kai Li,Lici A. Schurig-Briccio,Xinxin Feng,Ashutosh Upadhyay,Venugopal Pujari,Benoit Lechartier,Fabio L. Fontes,Hongliang Yang,Guodong Rao,Wei Zhu,Anmol Gulati,Joo Hwan No,Giovana Cintra,Shannon Bogue,Yi-Liang Liu,Katie Molohon,Peter Orlean,Douglas A. Mitchell,Lucio Freitas-Junior,Feifei Ren,Hong Sun,Tong Jiang,Yujie Li,Rey-Ting Guo,Stewart T. Cole,Robert B. Gennis,Dean C. Crick,Eric Oldfield

DOI: https://doi.org/10.1021/jm500131s

IF: 8.039

2014-01-01

Journal of Medicinal Chemistry

Abstract:We report the discovery of a series of new drug leads that have potent activity against Mycobacterium tuberculosis as well as against other bacteria, fungi, and a malaria parasite. The compounds are analogues of the new tuberculosis (TB) drug SQ109 (1), which has been reported to act by inhibiting a transporter called MmpL3, involved in cell wall biosynthesis. We show that 1 and the new compounds also target enzymes involved in menaquinone biosynthesis and electron transport, inhibiting respiration and ATP biosynthesis, and are uncouplers, collapsing the pH gradient and membrane potential used to power transporters. The result of such multitarget inhibition is potent inhibition of TB cell growth, as well as very low rates of spontaneous drug resistance. Several targets are absent in humans but are present in other bacteria, as well as in malaria parasites, whose growth is also inhibited.